NDX-1017
NDX-1017-0101-01
Phase 1 small_molecule completed
Quick answer
NDX-1017 for Alzheimer Disease is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BRIGHT MINDS BIOSCIENCES INC.
- Indication
- Alzheimer Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed